Alkermes hits 6-month high as schizophrenia drug fuels Q1 beat

Alkermes

27/04/2022 15:13

** Drugmaker's shares  ALKS.O  jump 11.2% to a six-month
high of $30.17 
    ** ALKS beats Q1 sales expectations, helped by strong demand
for its schizophrenia drug Lybalvi, which was approved last year
  urn:newsml:reuters.com:*:nPn5Y10jba
    ** Co reports Q1 total sales of $278.5 mln, versus Refinitiv
IBES estimates of $252.6 mln, the second straight quarterly beat
    ** Including session gains, stock has risen ~27% YTD

 (Reporting by Manas Mishra)
 ((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manaswrites15))